Alaunos Therapeutics
TCRT
155 hedge funds and large institutions have $298M invested in Alaunos Therapeutics in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 18 closing their positions.
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
26% more call options, than puts
Call options by funds: $3.19M | Put options by funds: $2.54M
3% more funds holding
Funds holding: 150 → 155 (+5)
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
0.01% less ownership
Funds ownership: 0.36% → 0.35% (-0.01%)
30% less capital invested
Capital invested by funds: $423M → $298M (-$125M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.57M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$1.47M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$1.36M |
| 4 |
Millennium Management
New York
|
+$1.15M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.11M |
| 2 |
MVP
Miller Value Partners
Sarasota,
Florida
|
-$4.72M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.17M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.56M |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
-$1.4M |
TCRT Hedge Fund Activity: Q2 2021 in Review
155 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2021, worth a combined $298M — down 30% from $423M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TCRT positions and 18 closed out — a net gain of 7 holders — while 47 added to existing stakes and 43 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.57M. The largest seller was BlackRock, cutting an estimated $7.11M.
- 155 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2021, up from 150 in Q1 2021.
- Funds reported $298M of Alaunos Therapeutics stock for Q2 2021, down 30% quarter-over-quarter.
- 25 funds opened new Alaunos Therapeutics positions in Q2 2021 and 18 closed out, a net change of +7 holders.
- The largest Alaunos Therapeutics buyer in Q2 2021 was Renaissance Technologies, an estimated $1.57M added.
- The largest Alaunos Therapeutics seller in Q2 2021 was BlackRock, an estimated $7.11M sold.
Based on aggregated 13F filings for Q2 2021.